CLINICAL_TRIALS
ClinicalTrials.gov record update
A Multicenter, Prospective Phase II Clinical Study of High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06971406
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:48.333896+00:00
- Published At
- 2025-05-14T00:00:00+00:00
- Record Updated At
- 2025-05-14
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Non Small Cell Lung Cancer", "EGFR Mutation", "Leptomeningeal Metastases", "Targeted Therapy"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-05-14"- protocolSection.identificationModule.nctId
"NCT06971406"- protocolSection.identificationModule.officialTitle
"A Multicenter, Prospective Phase II Clinical Study of High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis"- protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.